Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Yaping Chu and Jeffrey Kordower.
Yaping Chu
Connection Strength
11.634
Jeffrey Kordower
  1. Nigrostriatal tau pathology in parkinsonism and Parkinson's disease. Brain. 2023 Nov 25.
    View in: PubMed
    Score: 0.932
  2. Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10?Years CERE120 Delivery. Mov Disord. 2023 09; 38(9):1728-1736.
    View in: PubMed
    Score: 0.913
  3. Mixed pathology as a rule, not exception: Time to reconsider disease nosology. Handb Clin Neurol. 2023; 192:57-71.
    View in: PubMed
    Score: 0.876
  4. GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. Neurobiol Dis. 2021 06; 153:105298.
    View in: PubMed
    Score: 0.772
  5. Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain. 2020 03 01; 143(3):960-975.
    View in: PubMed
    Score: 0.720
  6. Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. Brain. 2019 11 01; 142(11):3565-3579.
    View in: PubMed
    Score: 0.703
  7. Do subjects with minimal motor features have prodromal Parkinson disease? Ann Neurol. 2018 03; 83(3):562-574.
    View in: PubMed
    Score: 0.627
  8. Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease. J Parkinsons Dis. 2016; 6(1):77-97.
    View in: PubMed
    Score: 0.539
  9. The prion hypothesis of Parkinson's disease. Curr Neurol Neurosci Rep. 2015 May; 15(5):28.
    View in: PubMed
    Score: 0.515
  10. Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. Neurobiol Dis. 2014 Sep; 69:1-14.
    View in: PubMed
    Score: 0.481
  11. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain. 2012 Jul; 135(Pt 7):2058-73.
    View in: PubMed
    Score: 0.422
  12. a-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol Dis. 2011 Jan; 41(1):71-82.
    View in: PubMed
    Score: 0.373
  13. Lewy body pathology in fetal grafts. Ann N Y Acad Sci. 2010 Jan; 1184:55-67.
    View in: PubMed
    Score: 0.356
  14. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009 Sep; 35(3):385-98.
    View in: PubMed
    Score: 0.342
  15. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis. 2007 Jan; 25(1):134-49.
    View in: PubMed
    Score: 0.285
  16. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.271
  17. Distribution of phosphorylated alpha-synuclein in non-diseased brain implicates olfactory bulb mitral cells in synucleinopathy pathogenesis. NPJ Parkinsons Dis. 2023 Mar 25; 9(1):43.
    View in: PubMed
    Score: 0.222
  18. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol. 2002 Aug 26; 450(3):203-14.
    View in: PubMed
    Score: 0.214
  19. In situ proximity labeling identifies Lewy pathology molecular interactions in the human brain. Proc Natl Acad Sci U S A. 2022 02 01; 119(5).
    View in: PubMed
    Score: 0.206
  20. Temporal evolution of microglia and a-synuclein accumulation following foetal grafting in Parkinson's disease. Brain. 2019 06 01; 142(6):1690-1700.
    View in: PubMed
    Score: 0.171
  21. Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathol Commun. 2017 06 16; 5(1):47.
    View in: PubMed
    Score: 0.149
  22. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017 Jan; 81(1):46-57.
    View in: PubMed
    Score: 0.145
  23. Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. J Comp Neurol. 2017 02 15; 525(3):498-512.
    View in: PubMed
    Score: 0.141
  24. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013 Aug; 136(Pt 8):2419-31.
    View in: PubMed
    Score: 0.114
  25. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord. 2011 Jan; 26(1):27-36.
    View in: PubMed
    Score: 0.095
  26. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. 2008 Dec 15; 23(16):2303-6.
    View in: PubMed
    Score: 0.083
  27. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008 May; 14(5):504-6.
    View in: PubMed
    Score: 0.079
  28. Neuropathological study 16 years after autologous adrenal medullary transplantation in a Parkinson's disease patient. Mov Disord. 2007 Aug 15; 22(11):1630-3.
    View in: PubMed
    Score: 0.075
  29. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis. 2007 Apr; 26(1):56-65.
    View in: PubMed
    Score: 0.073
  30. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol. 2006 Aug; 60(2):264-8.
    View in: PubMed
    Score: 0.070
  31. Extensive neuroprotection by choroid plexus transplants in excitotoxin lesioned monkeys. Neurobiol Dis. 2006 Aug; 23(2):471-80.
    View in: PubMed
    Score: 0.070
  32. RET expression does not change with age in the substantia nigra pars compacta of rhesus monkeys. Neurobiol Aging. 2006 Jun; 27(6):857-61.
    View in: PubMed
    Score: 0.065
  33. Effects of estrogen replacement therapy on cholinergic basal forebrain neurons and cortical cholinergic innervation in young and aged ovariectomized rhesus monkeys. J Comp Neurol. 2004 Apr 26; 472(2):193-207.
    View in: PubMed
    Score: 0.060
  34. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci. 2002 Jun 15; 22(12):4942-54.
    View in: PubMed
    Score: 0.053
  35. Widespread Striatal Delivery of GDNF from Encapsulated Cells Prevents the Anatomical and Functional Consequences of Excitotoxicity. Neural Plast. 2019; 2019:6286197.
    View in: PubMed
    Score: 0.042
  36. Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA. Mol Neurobiol. 2018 Nov; 55(11):8728-8737.
    View in: PubMed
    Score: 0.039
  37. Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins. Acta Neuropathol. 2017 May 19.
    View in: PubMed
    Score: 0.037
  38. PGC-1a Promoter Methylation in Parkinson's Disease. PLoS One. 2015; 10(8):e0134087.
    View in: PubMed
    Score: 0.033
  39. Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington's disease. Hum Mol Genet. 2015 Sep 15; 24(18):5285-98.
    View in: PubMed
    Score: 0.033
  40. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014 Sep; 10(5):571-81.
    View in: PubMed
    Score: 0.029
  41. Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Sci Rep. 2013; 3:2157.
    View in: PubMed
    Score: 0.027
  42. ?-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and ?-amyloid accumulation. Eur J Neurosci. 2010 Oct; 32(7):1223-38.
    View in: PubMed
    Score: 0.023
  43. Doublecortin-expressing cells persist in the associative cerebral cortex and amygdala in aged nonhuman primates. Front Neuroanat. 2009; 3:17.
    View in: PubMed
    Score: 0.022
  44. Doublecortin expression in adult cat and primate cerebral cortex relates to immature neurons that develop into GABAergic subgroups. Exp Neurol. 2009 Apr; 216(2):342-56.
    View in: PubMed
    Score: 0.021
  45. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther. 2008 Oct; 16(10):1737-44.
    View in: PubMed
    Score: 0.020
  46. Postmortem study of deep brain stimulation of the anterior thalamus: case report. Neurosurgery. 2008 Feb; 62(2):E530-2; discussion E532.
    View in: PubMed
    Score: 0.019
  47. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res. 2007 May 25; 1147:77-88.
    View in: PubMed
    Score: 0.018
  48. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol. 2006 Aug; 60(2):260-4.
    View in: PubMed
    Score: 0.018
  49. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis. 2006 Jan; 21(1):165-80.
    View in: PubMed
    Score: 0.016
  50. Chronic ischemic stroke model in cynomolgus monkeys: behavioral, neuroimaging and anatomical study. Neurol Res. 2003 Jan; 25(1):68-78.
    View in: PubMed
    Score: 0.014
  51. The immunophilin ligand GPI-1046 does not have neuroregenerative effects in MPTP-treated monkeys. Exp Neurol. 2002 Dec; 178(2):236-42.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.